• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

生长抑素类似物治疗导致分泌生长激素（GH）的大腺瘤显著缩小：一例报告及文献综述

Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.

作者信息

Kurahashi Kiyoe, Endo Itsuro, Kondo Takeshi, Morimoto Kana, Yoshida Sumiko, Kuroda Akio, Aihara Ken-Ichi, Matsuhisa Munehide, Nakajima Kohei, Mizobuchi Yoshifumi, Nagahiro Shinji, Abe Masahiro, Fukumoto Seiji

机构信息

Department of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan.

Diabetes Therapeutics and Research Center, Tokushima University, Japan.

出版信息

Intern Med. 2017 Sep 15;56(18):2455-2461. doi: 10.2169/internalmedicine.8223-16. Epub 2017 Aug 21.

DOI:10.2169/internalmedicine.8223-16
PMID:28824054
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5643174/
Abstract

Acromegaly is caused by excessive growth hormone secretion, usually from pituitary adenomas. Somoatostatin analogues are widely used as primary or adjunctive therapy in the management of acromegaly. In this report, we present a case with remarkable shrinkage of a tumor after relatively short-term octreotide long-acting release (LAR) administration. During the 30-month follow-up after starting octreotide LAR, there was no recurrence of acromegaly with remarkable shrinkage of the tumor on pituitary magnetic resonance imaging. A literature review of the predictors for tumor shrinkage after the administration of somatostatin analogues in patients with acromegaly is also discussed in relation to this case.

摘要

肢端肥大症是由生长激素分泌过多引起的，通常源于垂体腺瘤。生长抑素类似物被广泛用作肢端肥大症治疗的主要或辅助疗法。在本报告中，我们呈现了一例在相对短期给予长效奥曲肽（LAR）后肿瘤显著缩小的病例。在开始使用奥曲肽LAR后的30个月随访期间，肢端肥大症未复发，垂体磁共振成像显示肿瘤显著缩小。本文还结合该病例讨论了关于肢端肥大症患者使用生长抑素类似物后肿瘤缩小预测因素的文献综述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a069/5643174/b8ac0b71590e/1349-7235-56-2455-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a069/5643174/9219d298decf/1349-7235-56-2455-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a069/5643174/3eca634f00b9/1349-7235-56-2455-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a069/5643174/b8ac0b71590e/1349-7235-56-2455-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a069/5643174/9219d298decf/1349-7235-56-2455-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a069/5643174/3eca634f00b9/1349-7235-56-2455-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a069/5643174/b8ac0b71590e/1349-7235-56-2455-g003.jpg

相似文献

1
Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.生长抑素类似物治疗导致分泌生长激素（GH）的大腺瘤显著缩小：一例报告及文献综述
Intern Med. 2017 Sep 15;56(18):2455-2461. doi: 10.2169/internalmedicine.8223-16. Epub 2017 Aug 21.
2
Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.长效兰瑞肽和奥曲肽长效注射剂对既往未经治疗的肢端肥大症患者肿瘤缩小及生长激素分泌过多的长期影响。
Clin Endocrinol (Oxf). 2002 Jan;56(1):65-71. doi: 10.1046/j.0300-0664.2001.01438.x.
3
Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery.术前使用长效奥曲肽对生长激素分泌型垂体腺瘤及经蝶窦手术的影响
Chin Med Sci J. 2005 Mar;20(1):23-6.
4
Primary octreotide LAR therapy in GH-secreting pituitary adenoma.生长激素分泌型垂体腺瘤的长效奥曲肽初始治疗
J Indian Med Assoc. 2004 May;102(5):258, 260-1.
5
Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.肢端肥大症的术前奥曲肽治疗：最终生长激素（GH）浓度和垂体功能无改善。一项长期病例对照研究。
Acta Neurochir (Wien). 2005 May;147(5):485-93; discussion 493. doi: 10.1007/s00701-005-0511-9. Epub 2005 Apr 4.
6
[Evaluation of the efficacy of long-acting somatostatin analog as adjunctive therapy in patients with active acromegaly].[长效生长抑素类似物作为肢端肥大症活动期患者辅助治疗的疗效评估]
Przegl Lek. 2006;63(3):117-22.
7
Disappearance of a GH secreting macroadenoma, during long-term somatostatin analogue administration.在长期使用生长抑素类似物治疗期间，生长激素分泌型大腺瘤消失。
Exp Clin Endocrinol Diabetes. 2009 Jul;117(7):309-11. doi: 10.1055/s-0028-1086000. Epub 2008 Oct 7.
8
Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide.长效生长抑素类似物奥曲肽使分泌生长激素的垂体腺瘤发生可逆性缩小。
Arch Intern Med. 1989 Jun;149(6):1443-5.
9
Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.生长抑素受体亚型1在部分响应或抵抗生长抑素类似物长期治疗的患者来源的人生长激素分泌性垂体瘤中的表达及功能
Neuroendocrinology. 2004 Mar;79(3):142-8. doi: 10.1159/000077272. Epub 2004 Apr 16.
10
[Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].[奥曲肽长效注射剂治疗生长激素瘤患者的疗效评估]
Pol Arch Med Wewn. 2001 Aug;106(2):693-8.

本文引用的文献

1
Treatment of acromegaly in the era of personalized and predictive medicine.个性化与预测性医学时代的肢端肥大症治疗
Clin Endocrinol (Oxf). 2015 Jul;83(1):3-14. doi: 10.1111/cen.12731. Epub 2015 Mar 5.
2
Acromegaly: an endocrine society clinical practice guideline.肢端肥大症：内分泌学会临床实践指南。
J Clin Endocrinol Metab. 2014 Nov;99(11):3933-51. doi: 10.1210/jc.2014-2700. Epub 2014 Oct 30.
3
Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype.肢端肥大症的立体定向放射外科治疗：按腺瘤亚型划分的结果
Pituitary. 2015 Jun;18(3):326-34. doi: 10.1007/s11102-014-0578-5.
4
Somatostatin receptor ligands and resistance to treatment in pituitary adenomas.生长抑素受体配体与垂体腺瘤治疗抵抗。
J Mol Endocrinol. 2014 Jun;52(3):R223-40. doi: 10.1530/JME-14-0011. Epub 2014 Mar 19.
5
Novel pathway for somatostatin analogs in patients with acromegaly.肢端肥大症患者中生长抑素类似物的新途径。
Trends Endocrinol Metab. 2013 May;24(5):238-46. doi: 10.1016/j.tem.2012.11.007. Epub 2012 Dec 25.
6
Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.生长激素颗粒模式和生长抑素受体亚型 2A 与肢端肥大症术后生长抑素受体配体反应相关：一项大型单中心经验。
Pituitary. 2013 Dec;16(4):490-8. doi: 10.1007/s11102-012-0445-1.
7
Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly.T2 加权磁共振成像上垂体腺瘤的强度可预测新诊断的肢端肥大症患者对奥曲肽治疗的反应。
Clin Endocrinol (Oxf). 2012 Jul;77(1):72-8. doi: 10.1111/j.1365-2265.2011.04286.x.
8
Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly.奥曲肽 LAR 和兰瑞肽长效微球作为肢端肥大症术后治疗的比较。
Pituitary. 2012 Sep;15(3):398-404. doi: 10.1007/s11102-011-0335-y.
9
Pathogenesis of pituitary tumors.垂体肿瘤的发病机制。
Nat Rev Endocrinol. 2011 May;7(5):257-66. doi: 10.1038/nrendo.2011.40. Epub 2011 Mar 22.
10
Resistance to somatostatin analogs in acromegaly.肢端肥大症中生长抑素类似物的耐药性。
Endocr Rev. 2011 Apr;32(2):247-71. doi: 10.1210/er.2010-0002. Epub 2010 Dec 1.